cobas® eplex system: Resource center
Browse through a variety of resources and learn more about the cobas® eplex system, cobas® eplex BCID and cobas® eplex RP2 Panels*.
Virtual events
Eric Wenzler, PharmD, BCPS, BCIDP, AAHIVP, Assistant Professor, University of Illinois, Chicago
Sixto M. Leal Jr., MD, PhD, Director of Clinical Microbiology, University of Alabama at Birmingham and Todd McCarty, MD, Infectious Diseases Physician, University of Alabama at Birmingham
Joel E. Mortensen, Ph.D., director of the diagnostic infectious diseases testing laboratories, Cincinnati Children's Hospital
Breida Boyle, MB.B.Ch.B.A.O, FRCPI, FRCPath(UK), FFPath(RCPI), PG Dip. HIC (UK), consultant microbiologist, St. James Hospital, Department of Clinical Microbiology, Trinity College Dublin
Kevin M. McNabb, Ph.D., MT, director of microbiology, immunology and molecular testing, New Hanover Medical Center
Articles
Products
Publications
- Multicenter evaluation of the cobas® eplex respiratory pathogen panel
- Opportunities revealed for antimicrobial stewardship and clinical practice
- Comparison of cobas® eplex Respiratory Pathogen Panel
- A multicenter clinical study to demonstrate the diagnostic accuracy
- Clinical performance of the novel cobas® eplex Blood Culture ID Gram-Positive Panel
- Multicenter evaluation of a PCR-based digital microfluidics and electrochemical detection system
- Evaluation of microbiological performance and the potential clinical impact
- The clinical impact of implementing cobas® eplex blood culture panels
* This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2 and multiple respiratory viral and bacterial organisms and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Some products in the above articles, publications, webinars and more may be referenced as investigational or research use only and now are IVD.